Research programme: anticancer threpeutics - Genisphere

Drug Profile

Research programme: anticancer threpeutics - Genisphere

Alternative Names: FA-3DNA-siHuR; GL-231; GL-233; GL-238; GL-23X; GL-246; GL-2B2; GS-2A3

Latest Information Update: 14 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genisphere
  • Class Antineoplastics; Drug conjugates; RNA binding proteins; Small interfering RNA; Small molecules
  • Mechanism of Action DNA intercalators; RNA interference; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ovarian cancer
  • Research Breast cancer; Glioblastoma; Pancreatic cancer

Most Recent Events

  • 09 Jun 2016 Research programme: anticancer threpeutics - Genisphere is available for licensing as of 09 Jun 2016.
  • 09 Jun 2016 Early research in Glioblastoma,Breast cancer and Pancreatic cancer in USA (unspecified route)
  • 09 Jun 2016 Preclinical trials in Ovarian cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top